{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:48:36Z","timestamp":1782409716398,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011710","name":"Shaanxi Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2025JC-YBQN-1241"],"award-info":[{"award-number":["2025JC-YBQN-1241"]}],"id":[{"id":"10.13039\/501100011710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011710","name":"Shaanxi Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2024SF-YBXM-041"],"award-info":[{"award-number":["2024SF-YBXM-041"]}],"id":[{"id":"10.13039\/501100011710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jocn.2026.111959","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:59:13Z","timestamp":1773525553000},"page":"111959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk factors for drug-related ischemic stroke: an analysis of the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"148","author":[{"given":"Weili","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naibing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanzeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengli","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-050823-094312","article-title":"Contemporary management of acute ischemic stroke","volume":"76","author":"Ho","year":"2025","journal-title":"Annu Rev Med"},{"issue":"10","key":"10.1016\/j.jocn.2026.111959_b0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Feigin","year":"2024","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.jocn.2026.111959_b0015","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16422","article-title":"Small vessel disease burden and prognosis of recent subcortical ischaemic stroke differ by parent artery atherosclerosis","volume":"31","author":"Lin","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2026.111959_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.110915","article-title":"Association of the coexistence of intracranial atherosclerotic disease and cerebral small vessel disease with acute ischemic stroke","volume":"165","author":"Li","year":"2023","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jocn.2026.111959_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/STROKEAHA.120.033272","article-title":"Drugs associated with ischemic stroke","volume":"52","author":"Marto","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.jocn.2026.111959_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.1645","article-title":"Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke","volume":"327","author":"Ren\u00fa","year":"2022","journal-title":"J Am Med Assoc"},{"issue":"7","key":"10.1016\/j.jocn.2026.111959_b0035","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jth.12241","article-title":"Adherence to anticoagulant treatment with dabigatran in a real\u2010world setting","volume":"11","author":"Schulman","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcm.2014.09.001","article-title":"Warfarin pharmacogenetics","volume":"25","author":"Johnson","year":"2015","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/ATVBAHA.117.309919","article-title":"Elevated plasma factor IXa activity in premenopausal women on hormonal contraception","volume":"38","author":"Tanratana","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","article-title":"Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability","volume":"127","author":"Tang","year":"2020","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.jocn.2026.111959_b0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jocn.2026.111959_b0060","article-title":"Thrombosis risk with the use of hormonal contraception among women with thrombophilia: an updated systematic review","author":"Tepper","year":"2025","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.jocn.2026.111959_b0065","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.21873\/anticanres.13642","article-title":"Arterial thrombosis in cancer: spotlight on the neglected vessels","volume":"39","author":"Canale","year":"2019","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.jocn.2026.111959_b0070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ajh.27288","article-title":"Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a comparative systematic review and meta\u2010analysis","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.29801","article-title":"The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents","volume":"122","author":"Tully","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jocn.2026.111959_b0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jsps.2022.06.010","article-title":"Immune checkpoint inhibitors and potential risk of thromboembolic events: analysis of the WHO global database of individual case safety reports","volume":"30","author":"Alghamdi","year":"2022","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728222.2021.1869213","article-title":"The potential for immune checkpoint modulators in cerebrovascular injury and inflammation","volume":"25","author":"Kim","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"24","key":"10.1016\/j.jocn.2026.111959_b0090","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jocn.2026.111959_b0095","doi-asserted-by":"crossref","unstructured":"Morris, R., R. Ali, and F. Cheng, Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database. Current Drug Targets, 2024. 25(7): p. 454-464.","DOI":"10.2174\/0113894501290296240327081624"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000001056","article-title":"Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials","volume":"36","author":"Fey","year":"2024","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.jocn.2026.111959_b0105","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jocn.2026.111959_b0110","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v106.44546","article-title":"Cutaneous lymphoma associated with JAK inhibitors: a pharmacovigilance analysis of the FAERS database and literature review","volume":"106","author":"Lu","year":"2026","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-024-01913-0","article-title":"Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database","volume":"25","author":"Liu","year":"2024","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00228-023-03593-2","article-title":"Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study","volume":"80","author":"Nwanosike","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jocn.2026.111959_b0130","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40263-023-01052-1","article-title":"Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study","volume":"37","author":"Abou Kaoud","year":"2023","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2025018001","article-title":"Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study","volume":"10","author":"Eswaran","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40261-020-00901-x","article-title":"A systematic review and meta-analysis of the adverse effects of levonorgestrel emergency oral contraceptive","volume":"40","author":"Leelakanok","year":"2020","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jocn.2026.111959_b0145","article-title":"Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.jocn.2026.111959_b0150","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/clinem\/dgaf449","article-title":"Risk of death and adverse effects in patients on liothyronine: a multisource systematic review and meta-analysis","volume":"110","author":"Bahl","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jocn.2026.111959_b0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel adverse events of iloperidone: a disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database","volume":"14","author":"Subeesh","year":"2019","journal-title":"Curr Drug Saf"},{"issue":"6","key":"10.1016\/j.jocn.2026.111959_b0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.jocn.2026.111959_b0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpt.3098","article-title":"Postmarketing safety of sacituzumab govitecan: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"115","author":"Li","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jocn.2026.111959_b0180","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/14740338.2024.2368815","article-title":"Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database","volume":"23","author":"Qian","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70548","article-title":"Cardiovascular and metabolic adverse events of endocrine therapies in women with breast cancer: a disproportionality analysis of reports in the FDA adverse event reporting system","volume":"14","author":"Elshafie","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26462","article-title":"Comparing the risk of deep vein thrombosis of two combined oral contraceptives: Norethindrone\/ethinyl estradiol and drospirenone\/ethinyl estradiol","volume":"10","author":"Stalas","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jocn.2026.111959_b0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/OAJC.S161737","article-title":"Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database","volume":"9","author":"Madigan","year":"2018","journal-title":"Open Access J Contracept"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-14668-x","article-title":"Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database","volume":"25","author":"Yao","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.108173","article-title":"Real-world safety profile of direct oral anticoagulants (DOACs): Disproportionality analysis of major bleeding events","volume":"34","author":"di Biase","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jocn.2026.111959_b0210","first-page":"1","article-title":"Thromboembolic events associated with combined oral contraceptives: a real-world study based on the FDA adverse event reporting system (FAERS) database","author":"Liu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.jocn.2026.111959_b0215","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-018-0300-5","article-title":"Idarucizumab for reversal of dabigatran: single-center real-world experience","volume":"19","author":"Sheikh-Taha","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.jocn.2026.111959_b0225","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy\u2013associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.jocn.2026.111959_b0230","doi-asserted-by":"crossref","first-page":"277","DOI":"10.21037\/atm-20-3292","article-title":"The risk of venous thromboembolism in cancer patients receiving chemotherapy: a meta-analysis with systematic review","volume":"9","author":"Bao","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.111959_b0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-020-02101-5","article-title":"The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis","volume":"19","author":"Ye","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"8","key":"10.1016\/j.jocn.2026.111959_b0240","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.jocn.2026.111959_b0245","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40258-017-0318-x","article-title":"Economic evaluations of thrombophilia screening prior to prescribing combined oral contraceptives: a systematic and critical review","volume":"15","author":"Vernon","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.jocn.2026.111959_b0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.jocn.2026.111959_b0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/1076029616652724","article-title":"Drug-induced thrombophilic or prothrombotic states: an underestimated clinical problem that involves both legal and illegal compounds","volume":"23","author":"Girolami","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.jocn.2026.111959_b0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/bmjsrh-2023-201792","article-title":"Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception: a Cochrane systematic review","volume":"49","author":"Hansen","year":"2023","journal-title":"BMJ Sexual Reprod Health"},{"issue":"7","key":"10.1016\/j.jocn.2026.111959_b0265","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2026.111959_b0270","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2020.1730816","article-title":"Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research","volume":"20","author":"Ornello","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1016\/j.jocn.2026.111959_b0275","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jns.12660","article-title":"Paclitaxel alters the microvascular network in the central and peripheral nervous system of rats with chemotherapy\u2010induced painful peripheral neuropathy","volume":"29","author":"Zippo","year":"2024","journal-title":"J Peripher Nerv Syst"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:23:55Z","timestamp":1782408235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"alternative-id":["S0967586826001104"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111959","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for drug-related ischemic stroke: an analysis of the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111959"}}